Mirum Pharmaceuticals (MIRM)
NASDAQ:MIRM
Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$97.95
-$0.27(-0.64%)
At close: 4:00 PM EST
$97.95
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$40.00 - $110.49
Previous CloseN/A
Volume92.82K
Average Volume (3M)863.85K
Market Cap
$6.38B
Enterprise Value$5.33B
Total Cash (Recent Filing)$383.33M
Total Debt (Recent Filing)$319.45M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
May 06, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding60,341,618
10 Day Avg. Volume581,537
30 Day Avg. Volume863,845
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue10.23
Enterprise Value/Gross Profit12.67
Enterprise Value/Ebitda382.25
Forecast
1Y Price Target
$134.22Price Target Upside37.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$644.89M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnalyst cites that volixibat produced a larger placebo-adjusted reduction in itch versus a competing bile acid transporter inhibitor in mid-stage data, indicating potential for superior symptomatic benefit if confirmed in pivotal studies.
Commercial PerformanceAnalyst highlights that reported product sales exceeded expectations driven by strong Livmarli demand and describes company sales guidance as conservative, implying upside if commercial momentum continues.
Product Formulation ExpansionAnalyst notes that approval of a tablet formulation for Livmarli in major markets could expand use beyond a pediatric liquid, simplify dosing for adults, and improve patient adherence leading to broader uptake.
Bears Say
Competition And Execution RiskAnalyst points out that a competing bile acid transporter inhibitor is further along in the regulatory process and that challenges in identifying eligible patients could constrain uptake and trial enrollment, creating commercial and execution risk.
Regulatory Pathway RiskAnalyst warns that regulators are likely to require a confirmatory late-stage study for pruritus approval, which could delay market access and extend development uncertainty.
Safety And TolerabilityAnalyst observes a somewhat higher rate of diarrhea with volixibat compared with a competitor, creating a tolerability risk that could affect patient retention and prescribing patterns.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $40.00 and its highest was $110.48 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $6.38B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is May 06, 2026 which is today.
How were Mirum Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 60,341,618 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$134.22 (37.03% Upside)
$134.22 (37.03% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 273.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 12.5%
Last 30 Days ▲ 12.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.51%
12-Months-Change
Fundamentals
Return on Equity
-8.53%
Trailing 12-Months
Asset Growth
25.65%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive operational and commercial story: strong 2025 revenue growth (55% YoY), improved commercial margins (~55%), a healthy cash position and successful financing, multiple regulatory approvals, and an expanded pipeline with several near-term potentially registrational readouts. Key risks include a planned material increase in R&D spend (approximately $150M tied to brolobitug) compressing expenses into 2026, a deceleration in revenue growth implied by 2026 guidance (~21%–25% vs 55% in 2025), some region-specific revenue headwinds (Japan), and clinical/regulatory and competitive uncertainties for upcoming programs. Overall, the company appears well funded and operationally strong but will face elevated near-term spend and execution risk around trial readouts and regulatory interactions.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$134.22
▲(37.03% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Ownership Overview
8.03% Insiders
25.62% Mutual Funds
2.87% Other Institutional Investors
50.33% Public Companies and
Individual Investors